ABSTRACT Objectives: To examine whether the use of statins is associated with the incidence of type 2 diabetes (T2D) and changes in glucose metabolism among individuals at high risk for T2D participating in 1-year lifestyle intervention in primary healthcare setting.
INTRODUCTION
Statin therapy is effective in the primary and secondary prevention of cardiovascular diseases (CVD). [1] [2] [3] Recently, a slightly increased
ARTICLE SUMMARY Article focus
▪ Statin therapy has been suggested to slightly increase the risk of type 2 diabetes (T2D). It is not known whether this increased risk could be counteracted by lifestyle intervention. ▪ In this paper, we report the results of the analyses of use of statins and their association to the incidence of T2D and changes in glucose metabolism among individuals at high risk for T2D participating in lifestyle intervention in primary healthcare.
Key messages
▪ The incidence of T2D did not differ between the statin users and non-users. Fasting glucose increased in statin users compared to non-users and remained significant even after adjustment for sex, age, baseline fasting glucose, the presence of cardiovascular disease (CVD), use of antihypertensive and/or coronary artery disease medication, weight and 1-year weight change. ▪ The finding that fasting glucose slightly increased in statin users in spite of lifestyle interventions suggests that the use of statins might have unfavourable effects on glucose metabolism and that statins might hamper beneficial effects of lifestyle intervention in people at high risk of T2D.
Strengths and limitations of this study
▪ Implementation project of the national diabetes prevention programme in Finland. (FIN-D2D) is the first national effort to implement the prevention of diabetes in a primary healthcare setting and as far as we know this is the first study to examine the association of use of statins and T2D risk in high-risk individuals for T2D who participated in the lifestyle intervention programme. ▪ High number of individuals who were screened at baseline did not participate in the 1-year follow-up examination. ▪ The use of statins was based on self-report.
Because of the observational data, we cannot elicit a causal relationship.
type 2 diabetes (T2D) risk has been linked to the use of statins, [4] [5] [6] [7] although the West of Scotland Coronary Prevention Study (WOSCOPS) showed that statin users had a 30% reduction of the hazard of becoming diabetic. 8 However, recent meta-analyses show that the risk of T2D is 9-13% higher in statin users compared to non-users, 4 7 and the effect has been shown to be dose dependent, 9 and age dependent. 7 T2D is shown to be prevented or delayed by lifestyle counselling aimed at weight reduction, healthy diet and increase in physical activity in controlled lifestyle intervention trials. [10] [11] [12] [13] [14] We recently carried out a 1-year lifestyle intervention programme, FIN-D2D, in primary healthcare settings in Finland to find out whether lifestyle interventions work in real life as well. 15 This study also included a reasonable number of statin users and gave us an impetus to study whether statin therapy had associations with the incidence of T2D and changes in glucose metabolism during the 1-year follow-up among individuals at high risk for T2D participating in lifestyle intervention in primary healthcare. This study belongs to the implementation project of  the Programme for the Prevention of T2D in Finland  2003-2008 (FIN-D2D) . 16 17 In total, 400 primary healthcare centres and occupational healthcare outpatient clinics participated in the programme. 15 One of the principal aims of the FIN-D2D was to screen for individuals at high risk of T2D, 16 by using a modified Finnish Diabetes Risk Score test (FINDRISC), 15 18 19 with a cut-off point of 15 or more and history of impaired fasting glucose (IFG), impaired glucose tolerance (IGT), cardiovascular events or gestational diabetes. 15 Lifestyle counselling was offered to high-risk individuals in order to reduce their T2D risk. There was no randomisation, instead an opportunistic screening process was conducted and participants volunteered, thus they provided oral consent for willingness of taking part in this national programme carried out within primary care to prevent diabetes in the normal clinical settings. Because from the participants' point of view, they were not participating in a 'study'; there was no need to ask for a separate written informed consent from them. Nevertheless, all participants received written information on the FIN-D2D and they were informed of the data collection. As for the ethical approval, the National Public Health Institute applied for and obtained the permission from the Ministry of Social Affairs and Health for the purposes of evaluation and research to collect register-based morbidity data on FIN-D2D participants from primary care information systems.
MATERIAL AND METHODS
Lifestyle counselling was performed either in group sessions or individually. Local resources had an effect on the number and frequency of intervention visits. However, individual visits were planned according to individuals' needs, and the following topics and items were included: weight control, meal frequency and quality, for example, use of dietary fibre, fat and salt, physical activity, smoking, alcohol use and diabetes as a disease in general. Group sessions were mainly weight maintenance or exercise groups and lectures concerning diabetes and lifestyle changes. 15 17 After identification individuals at high risk for T2D were referred to health check-ups. They were asked to fill in a questionnaire on background health and lifestyle information before the health check-up. Local nurses in primary healthcare measured weight (to the nearest 0.1 kg), height (to the nearest cm), systolic and diastolic blood pressure (BP) (mm Hg) and gave brief motivationbuilding and counselling for lifestyle changes, 17 based on the principles of the Finnish Diabetes Prevention Study (DPS). 20 Body mass index (BMI) was calculated by weight divided by height (kg/m 2 ). 15 Weight loss during follow-up was dichotomised by using median to ≤0.80 or >0.80 kg for both genders. Oral glucose tolerance test (OGTT) was carried out in the morning after overnight fast with a glucose load of 75 g. Fasting and 2 h samples were collected from venous or capillary blood samples. At the baseline 80% and at the follow-up 85% were plasma venous samples. Corresponding figures for capillary samples were 20% and 15%, respectively. 15 Glucose tolerance status was classified by using World Health Organization (WHO) 1999 criteria. 21 Enzymatic methods were performed locally to determine plasma lipids and lipoproteins (mmol/l). 15 The use of lipid-lowering medication, antihypertensive and coronary artery disease medication was verified at the health check-up at baseline from prescriptions if possible. Individuals whose lipid-lowering medication had been initiated 120 days before the first visit or before the midway of the 1-year follow-up (no later than 270 days after the first visit) were regarded as users at the baseline. Statins are used almost exclusively for the treatment of dyslipidaemias in Finland. 22 In 2010, 93 035 individuals had reimbursement of drug costs under the Special Refund Category for dyslipidaemia associated with chronic coronary artery disease for HMG-CoA reductase inhibitors, while the corresponding numbers for fibrates and bile acid sequestrates were only 573 and 104, respectively. 23 Thus, we had a good reason to assume that lipid-lowering medication included statins only. If an individual used antihypertensive or coronary artery disease medication or both at the baseline he/she was classified as a user. CVD (heart failure, angina pectoris, coronary artery disease, myocardial infarction, heart bypass surgery and angioplasty) were asked by the questionnaire. If an individual had one of these diseases or abnormalities, he/she was considered as having CVD.
In total, 10 149 (3379 men and 6770 women) high-risk individuals aged 18- . Of these individuals, 444 had screendetected T2D, while 638 individuals did not participate in the OGTT at the baseline and were excluded from this study. Thus 2798 individuals participated in this study. 15 There were altogether 484 (17.3%) statin users at baseline among them. Twenty-six of them (5.4%) had started statin use no later than 270 days after the first visit.
Statistical analyses
Statistical analyses were performed by using SAS (V.9.2) for Windows and they were based on percentage distributions and χ 2 test and independent sample t test. Analysis of covariance (ANCOVA) was used to study the differences between the statin users and non-users in changes of fasting glucose values during the follow-up after adjusting for age, sex, weight, CVD disease, use of antihypertensive and/or coronary artery disease medication and fasting glucose at baseline and 1-year weight change as a continuous variable. Furthermore, separate logistic regression analyses were conducted for statin users and non-users to study the effect of weight loss (≤0.8 or >0.8 kg) on T2D risk after adjusting for age, sex, weight, CVD diseases, use of above-mentioned medication and glucose tolerance and at the baseline.
RESULTS
There were more men than women using statins at baseline (23% vs 14.5%, p<0.001). Statin users were older than non-users (table 1) . In addition, statin users had lower BMI, diastolic BP, total cholesterol, high-density lipoprotein (HDL) cholesterol and low-density lipoprotein (LDL) cholesterol than non-users at the baseline, whereas the levels of triglycerides, fasting glucose and 2 h glucose were higher in statin users compared to non-users (table 1) . Bivariate analyses between statin use and changes in cardio-metabolic characteristics showed that the changes in weight, BMI, systolic and diastolic BP, total, HDL and LDL cholesterol, triglycerides and 2 h glucose were similar in statin users and non-users, the only exception being in the change of fasting glucose. Fasting glucose level increased by 0.08 mmol/l during the follow-up in statin users but remained unchanged in non-users (table 2) , the difference being 0.074 mmol/l (95% CI 0.014 to 0.134) between the groups. The difference was significant even after adjustment for age, sex and fasting glucose at the baseline ( p=0.006) and after adding weight and CVD at the baseline ( p=0.015), and even when weight change ( p=0.026) and antihypertensive and/or coronary artery disease medication were added to the model ( p=0.042). Figure 1 presents the changes in fasting and 2 h glucose in statin users and non-users according to weight loss. In individuals whose weight loss was ≤0.8 kg, fasting glucose increased more in statin users compared to non-users ( p=0.055 after adjustment for age, sex, weight, CVD, medication and fasting glucose at the baseline). In those with weight loss of >0.8 kg, the reduction in fasting glucose was not statistically significantly different between statin users and non-users ( p=0.330 after adjustment, figure 1).
Statin therapy and incidence of T2D
A total of 7.5% (n=31) of the individuals who were statin users developed T2D during the follow-up compared to 6.5% (n=126) of non-users ( p=0.442). OR was 1.17 (95% CI 0.78 to 1.76) for users compared to non-users. Logistic regression analyses showed that only in statin non-users, weight loss was associated statistically significantly with the reduction of T2D even after adjustment for age, sex, weight, CVD, use of antihypertensive and or coronary artery disease medication and glucose tolerance status at the baseline (table 3) . However, the corresponding interaction test for statin users vs non-users was not statistically significant, suggesting that the association was not different in these two groups. In both statin users and non-users, IGT at baseline predicted a very high risk of developing T2D (table 3) .
DISCUSSION
Our results showed that the incidence of T2D during the 1-year follow-up did not differ between statin users and non-users. Interestingly, however, use of statins was related to increase in fasting glucose, and the change in fasting glucose was significantly different between these two groups even after adjustment for age, sex, weight, CVD disease, fasting glucose and use of antihypertensive and/or coronary artery disease medication at baseline and weight change.
As far as we know, this is the first study examining the association of lifestyle intervention on the risk of T2D according to the use of statins. This question is of utmost clinical importance since we now know that T2D is preventable by lifestyle changes. [10] [11] [12] [13] [14] A slight increase in fasting glucose during the follow-up in statin users in our study is in line with the findings from a prospective follow-up study comprising both diabetic and nondiabetic individuals without any lifestyle intervention. 24 In addition, another study also showed slight increase in fasting glucose in diabetic patients. 25 In our study fasting glucose increased by 0.08 mmol/l in statin users, whereas there was a slight decrease in 2 h glucose values in both groups after 1-year of follow-up. An increase in fasting glucose in statin users suggests deterioration in insulin secretion capacity in statin users. 26 Besides its putative effect on insulin secretion statins may also interfere with insulin sensitivity. 27 Nevertheless, in this study, 2 h glucose values, reflecting insulin sensitivity, were similarly decreased in statin users and non-users. It is not known whether statins have any acute effects on fasting glucose level, and we do not know whether people in our study had taken statin tablets in the morning or evening. From the clinical point of view, we want to emphasise even more intensive lifestyle interventions, 14 28 for high-risk patients using statins in order to prevent T2D. We also highlight that the role of lifestyle in the prevention of T2D in statin users should be investigated in larger intervention studies with longer follow-up.
The strength of our study is that glucose tolerance status was based on the OGTT, 21 and that IGT, that is, post-challenge hyperglycaemia, was strongly related to the development of T2D. Note that this information is missing from all previous studies that have investigated the relation between statins and T2D risk. In addition, the advantage of our study was that we were able to examine the changes in various cardio-metabolic risk factors according to the use of statins. The main shortcomings were that a high number of individuals who were screened at baseline did not participate in the intervention programme, 15 and thus the present results can be generalised only to a subgroup of high-risk individuals who also may present highly motivated individuals. Furthermore, the number of statin users was quite small and the use of statins was self-reported and not based on health records, which is why we did not have detailed information on the agents and doses used. We are also unable to say how long these individuals had used statins. We also conducted analyses on the use of statins and their association to changes in glucose metabolism and T2D risk excluding those 26 individuals who started to use statins no later than 270 days after the first visit. These results were very similar (data not shown) to findings presented here. Due to the nature of our data we cannot elicit a causal relationship. In addition, our study is likely to be underpowered to demonstrate any statistical difference in T2D risk according to the use of statins due to the short follow-up period. There may also be other factors (eg, variations in how the interventions were implemented in the centres) that may have an effect on the associations of statins and fasting glucose which we were not able to take into account in our study.
In summary, statins may have unfavourable effects on glucose metabolism and hamper the beneficial effects of lifestyle intervention in people at high risk of T2D, but the benefits of statin therapy for the prevention of CVD in people with an increased risk are still unequivocal. Ethics approval Ministry of Social Affairs and Health in Finland gave the permission to collect data from healthcare units specifically for scientific evaluation purposes to National Public Health Institute.
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